Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection

D. Smith, M. M. Berrey, M. Robertson, D. Mehrotra, M. Markowitz, L. Perrin, N. Clumeck, A. Lazzarin, B. Burckhardt, R. Weber, L. Corey, D. A. Cooper

Research output: Contribution to journalArticlepeer-review

Abstract

Forty-seven patients presenting with primary human immunodeficiency virus (HIV) infection were treated with zidovudine 200 mg 3 times a day, lamivudine 150 mg 2 times a day, and indinavir 800 mg 3 times a day for 1 year. From a mean pretreatment viral RNA level of 4.93 log10 copies/mL, the proportions of patients having 10 copies/mL at weeks 8 and 52, respectively. CD4 cell counts increased, from a mean of 546 cells/mm3, by 142 cells/mm3 at week 24 and by 210 cells/mm3 at week 52. Three patients discontinued the study because of drug-related toxicity. Six (12.8%) patients had adverse experiences associated with nephrolithiasis. Combination therapy with zidovudine, lamivudine, and indinavir during primary HIV infection results in a profound and sustained reduction in virus load with concurrent recovery of the CD4 cell population.

Original languageEnglish
Pages (from-to)950-954
Number of pages5
JournalJournal of Infectious Diseases
Volume182
Issue number3
DOIs
Publication statusPublished - 2000

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Fingerprint

Dive into the research topics of 'Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection'. Together they form a unique fingerprint.

Cite this